Integra LifeSciences (NASDAQ:IART) Stock Price Down 4.9% - Here's Why

Key Points

• Integra LifeSciences Holdings Corporation's stock price fell by 4.9%, trading as low as $14.74 after closing at $15.38, with a significant drop in trading volume.
• The company reported $0.45 EPS for the last quarter, surpassing the consensus estimate, but showed a 30.87% negative net margin year-over-year.
• Institutional investors currently hold 84.78% of Integra LifeSciences' shares, reflecting continued interest and changes in ownership among major stakeholders.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) were down 4.9% during mid-day trading on Friday . The company traded as low as $14.74 and last traded at $14.63. Approximately 213,085 shares changed hands during trading, a decline of 80% from the average daily volume of 1,047,780 shares. The stock had previously closed at $15.38.

Integra LifeSciences Stock Performance

The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. The business has a 50-day moving average price of $13.81 and a 200-day moving average price of $15.21. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -2.16 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm had revenue of $415.61 million for the quarter, compared to the consensus estimate of $395.06 million. During the same period in the prior year, the firm earned $0.63 EPS. The firm's revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, sell-side analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds have recently modified their holdings of IART. Caitong International Asset Management Co. Ltd boosted its stake in shares of Integra LifeSciences by 205.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company's stock worth $38,000 after acquiring an additional 2,108 shares in the last quarter. Osaic Holdings Inc. raised its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company's stock worth $51,000 after purchasing an additional 1,104 shares during the last quarter. AlphaQuest LLC acquired a new position in shares of Integra LifeSciences during the 2nd quarter worth about $73,000. EMC Capital Management acquired a new position in shares of Integra LifeSciences during the 2nd quarter worth about $75,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company's stock worth $98,000 after purchasing an additional 6,814 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.